학술논문
Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy.
Document Type
Article
Source
Subject
*DIABETIC retinopathy
*RETINAL vein occlusion
*VASCULAR endothelial growth factor antagonists
*MEDICAL practice
*ENDOTHELIAL growth factors
*OFF-label use (Drugs)
*RETINAL artery occlusion
*
*
*
*
*
*
Language
ISSN
1177-5467
Abstract
From a treatment perspective, all patients had received anti-VEGF therapy prior to brolucizumab, and most patients had also been treated with triamcinolone acetonide. After treatment options were discussed with patients, each patient received a brolucizumab 6mg IVI following a standardized injection protocol, which includes the use of a sterile speculum, povidone-iodine administration, and topical proparacaine application accompanied with a lidocaine gel application using a cotton swab. For the patient series reported here, every treated patient had shown progressive macular edema in spite of repetitive, short interval (q 2 to 3 week), combined anti-VEGF and triamcinolone acetonide treatment. Results A total of 110 eyes from 98 patients (52 men, 46 women) were injected with brolucizumab, including 51 Caucasian patients (52%), 42 Hispanic patients (42.9%), 3 African American patients (3.1%), and 2 Asian patients (2%). [Extracted from the article]